Tyra Biosciences, Inc. (TYRA) Reports In-Line Q3 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. CVS
9. SPY
10. XYZ

Go back to Tyra Biosciences, Inc. (TYRA) Reports In-Line Q3 EPS

Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights

November 5, 2025 4:05 PM EST

- Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 -

- Expanded development of dabogratinib into low-grade upper tract urothelial carcinoma (LG-UTUC); IND cleared with U.S. FDA -

- Cash, cash equivalents, and marketable securities of $274.9 million at Q3 2025; runway through at least 2027 -

CARLSBAD, Calif., Nov. 5, 2025 /PRNewswire/ --... More